The role of hormonal therapy in gynecological cancers-current status and future directions

Area of Science:

• Gynecologic Oncology
• Endocrinology
• Medical Oncology

Background:

• Many gynecological cancers (ovarian, endometrial, sarcomas) express estrogen/progesterone receptors.
• Hormonal therapies like progestogens and tamoxifen have variable efficacy in recurrent/metastatic disease.
• Aromatase inhibitors are effective and well-tolerated in hormone-receptor-positive breast cancer.

Purpose of the Study:

• To review current evidence on hormonal therapies, including aromatase inhibitors, for gynecological cancers.
• To highlight the uncertain role and limited study of aromatase inhibitors in this context.
• To identify gaps in knowledge regarding their use.

Main Methods:

• Literature review of studies on hormonal therapies in gynecological cancers.
• Analysis of evidence for aromatase inhibitor activity in hormone-sensitive gynecological malignancies.
• Identification of clinical trials and case reports.

Main Results:

• Estrogen and/or progesterone receptor expression is common in several gynecological cancers.
• Hormonal therapies demonstrate activity but with variable response rates.
• Aromatase inhibitors show potential but require further investigation.

Conclusions:

• Aromatase inhibitors may offer a therapeutic option for hormone-sensitive gynecological cancers.
• More research is essential to establish the role and optimize the use of aromatase inhibitors.
• Understanding receptor status is crucial for guiding hormonal therapy decisions.